Ovagen vs MGF (Mechano Growth Factor)
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
OvagenAnabolic & IGF
MGF (Mechano Growth Factor)- Summary
- Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
- MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Native MGF: minutes. PEG-MGF: ~3 days
- Admin Route
- SubQ, Oral
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 200–400 mcg
- Frequency
- Daily for 10–30 days
- 1–2 times per week
- Key Benefits
- Hepatoprotective effects against toxic, viral, and metabolic liver damage
- Promotes hepatocyte regeneration and liver tissue repair
- May reduce liver fibrosis progression
- Supports liver metabolic function and detoxification capacity
- Anti-aging effects on hepatic tissue
- Useful in NAFLD/MASH supportive protocols
- Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
- Activates muscle satellite cells for repair and growth
- Accelerates recovery from muscle damage
- Synergistic with IGF-1 LR3 (different mechanisms)
- Promotes muscle hypertrophy specifically at exercised muscles
- Faster recovery between training sessions
- Potential for injury repair in connective tissue
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No clinically significant hepatotoxicity reported
- Muscle soreness (satellite cell activation)
- Injection site irritation
- Hypoglycemia risk (modest, less than IGF-1 LR3)
- Stacks With
- —
- —